U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C41H64O14
Molecular Weight 780.9385
Optical Activity UNSPECIFIED
Defined Stereocenters 21 / 21
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Digoxin

SMILES

[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]4CC[C@@]5(C)[C@]([H])(CC[C@]6([H])[C@]5([H])C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4

InChI

InChIKey=LTMHDMANZUZIPE-PUGKRICDSA-N
InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1

HIDE SMILES / InChI
Molecular Formula C41H64O14
Molecular Weight 780.9385
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 21 / 21
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/digoxin.html

Digoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Digoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium. The sodium calcium exchanger (NCX) in turn tries to extrude the sodium and in so doing, pumps in more calcium. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.

CNS Activity

Originator

Approval Year

1954
117
Targets

Targets

Primary TargetPharmacologyConditionPotency
Y79
1
Target ID: CHEMBL613820
Inhibitor
8297
 0.1 µM [IC50]
Glucose-6-phosphate 1-dehydrogenase
12
Target ID: P05370
Gene ID: 24377.0
Gene Symbol: G6pdx
Target Organism: Rattus norvegicus (Rat)
Inhibitor
8297
 0.09 mM [IC50]
6-phosphogluconate dehydrogenase, decarboxylating
29
Target ID: P85968
Gene ID: 1.00360176E8
Gene Symbol: Pgd
Target Organism: Rattus norvegicus (Rat)
Inhibitor
8297
 0.14 mM [IC50]
Inhibitor
8297
 0.22 mM [IC50]
Inhibitor
8297
 0.4 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
LANOXIN

Approved Use

LANOXIN is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. Increasing myocardial contractility in pediatric patients with heart failure. Control of resting ventricular rate in adults with chronic atrial fibrillation.

Launch Date

1953
Primary
Approved
8429
LANOXIN

Approved Use

LANOXIN is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. Increasing myocardial contractility in pediatric patients with heart failure. Control of resting ventricular rate in adults with chronic atrial fibrillation.

Launch Date

1953
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.32 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/18823299
0.25 mg single, oral
dose: 0.25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIGOXIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.5 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/18823299
0.25 mg single, oral
dose: 0.25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIGOXIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
42 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020405s013lbl.pdf
unknown, intravenous
 DIGOXIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
75%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020405s013lbl.pdf
unknown, intravenous
 DIGOXIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
22.5 mg single, oral
Overdose
Dose: 22.5 mg
Route: oral
Route: single
Dose: 22.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/2592582
Page: p.901, 902
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2592582
Page: p.901, 902
Disc. AE: Vomiting, Lethargy...
AEs leading to
discontinuation/dose reduction:
Vomiting
Lethargy
Tachycardia
Sources:
https://pubmed.ncbi.nlm.nih.gov/2592582
Page: p.901, 902
25 mg single, oral
Overdose
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
healthy, 26
n = 1
Health Status: healthy
Age Group: 26
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
Disc. AE: Blurred vision, Sinus bradycardia...
AEs leading to
discontinuation/dose reduction:
Blurred vision
Sinus bradycardia
Electrocardiogram ST segment depression
Heart block
Ventricular tachycardia
Ventricular fibrillation
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
18 mg single, oral
Overdose
Dose: 18 mg
Route: oral
Route: single
Dose: 18 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
healthy, 41
n = 1
Health Status: healthy
Age Group: 41
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
Disc. AE: Hyperkalemia, Nausea...
AEs leading to
discontinuation/dose reduction:
Hyperkalemia
Nausea
Vomiting
Lethargy
Atrioventricular block
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
AEs

AEs

AESignificanceDosePopulation
Lethargy Disc. AE
22.5 mg single, oral
Overdose
Dose: 22.5 mg
Route: oral
Route: single
Dose: 22.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/2592582
Page: p.901, 902
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2592582
Page: p.901, 902
Tachycardia Disc. AE
22.5 mg single, oral
Overdose
Dose: 22.5 mg
Route: oral
Route: single
Dose: 22.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/2592582
Page: p.901, 902
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2592582
Page: p.901, 902
Vomiting Disc. AE
22.5 mg single, oral
Overdose
Dose: 22.5 mg
Route: oral
Route: single
Dose: 22.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/2592582
Page: p.901, 902
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2592582
Page: p.901, 902
Blurred vision Disc. AE
25 mg single, oral
Overdose
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
healthy, 26
n = 1
Health Status: healthy
Age Group: 26
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
Electrocardiogram ST segment depression Disc. AE
25 mg single, oral
Overdose
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
healthy, 26
n = 1
Health Status: healthy
Age Group: 26
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
Heart block Disc. AE
25 mg single, oral
Overdose
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
healthy, 26
n = 1
Health Status: healthy
Age Group: 26
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
Sinus bradycardia Disc. AE
25 mg single, oral
Overdose
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
healthy, 26
n = 1
Health Status: healthy
Age Group: 26
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
Ventricular fibrillation Disc. AE
25 mg single, oral
Overdose
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
healthy, 26
n = 1
Health Status: healthy
Age Group: 26
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
Ventricular tachycardia Disc. AE
25 mg single, oral
Overdose
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
healthy, 26
n = 1
Health Status: healthy
Age Group: 26
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6409318
Page: p.393
Atrioventricular block Disc. AE
18 mg single, oral
Overdose
Dose: 18 mg
Route: oral
Route: single
Dose: 18 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
healthy, 41
n = 1
Health Status: healthy
Age Group: 41
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
Hyperkalemia Disc. AE
18 mg single, oral
Overdose
Dose: 18 mg
Route: oral
Route: single
Dose: 18 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
healthy, 41
n = 1
Health Status: healthy
Age Group: 41
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
Lethargy Disc. AE
18 mg single, oral
Overdose
Dose: 18 mg
Route: oral
Route: single
Dose: 18 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
healthy, 41
n = 1
Health Status: healthy
Age Group: 41
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
Nausea Disc. AE
18 mg single, oral
Overdose
Dose: 18 mg
Route: oral
Route: single
Dose: 18 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
healthy, 41
n = 1
Health Status: healthy
Age Group: 41
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
Vomiting Disc. AE
18 mg single, oral
Overdose
Dose: 18 mg
Route: oral
Route: single
Dose: 18 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
healthy, 41
n = 1
Health Status: healthy
Age Group: 41
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/490791
Page: p.2100
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OATP1B1
788

OATP1B3
706
CYP450
65

P-gp
1537

OATP1B3
350
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OATP1B3
715
 yes [IC50 1 uM]
OATP1B1
803
 yes [IC50 7.9 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP450
65
 no
OATP1B3
350
 yes
P-gp
1537
 yes
yes (co-administration study)
Comment: Many drug drug interactions. See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020405s015lbl.pdf#page=11
Page: 10.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:4551
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4551
MolPort
MolPort-002-536-760
https://www.molport.com/shop/molecule-link/MolPort-002-536-760
ZINC
ZINC000242548690
http://zinc15.docking.org/substances/ZINC000242548690
eMolecules
4849372
https://www.emolecules.com/cgi-bin/more?vid=4849372
eMolecules
502132
https://www.emolecules.com/cgi-bin/more?vid=502132
PubMed

PubMed

TitleDatePubMed
[Digitalis intoxication: specifity and significance of cardiac and extracardiac symptoms. part I: Patients with digitalis-induced arrhythmias (author's transl)].
1977 Mar
26-10 Fab-digoxin complex: affinity and specificity due to surface complementarity.
1993 Nov 1
Structure and specificity of the anti-digoxin antibody 40-50.
1995 Apr 28
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.
2005 Apr
Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans.
2006 Jan
Patents

Patents

JP1025792A
1
JP2002255822A
8
JP2002511777A
414
JP2002536415A
10
JP2002537317A
97
JP2003286170A
11
JP2003508349A
45
JP2004534255A
1
JP2005143475A
1
JP2005525149A
1
JP2006523667A
4
JP2007506404A
1
JP2007524644A
48
JP2007525670A
148
JP2009515970A
1
JP2009519467A
53
JP2009527289A
25
JP2010273562A
1
JP2011510067A
57
JP2921989B2
6
JP2950613B2
1
JP3224538B2
1
JP4606172B2
28
JP4722295B2
104
JP4739217B2
51
JP4763957B2
87
JP4804361B2
32
JPH01295165A
2
JPH01321360A
1
JPH0261560A
1
JPH03240732A
3
JPH05249112A
2
JPH05255400A
1
JPH05294990A
1
JPH06113832A
1
JPH061798A
3
JPH0637A
5
JPH07301632A
3
JPH0841100A
1
JPH08501298A
3
JPH0853497A
1
JPH0899894A
6
JPH107566A
4
JPH11322613A
1
JPS5262267A
1
JPS5762297A
3
JPS5971687A
1
JPS60105965A
1
JPS60166697A
1
JPS60183558A
1
JPS6028987A
1

Sample Use Guides

In Vivo Use Guide
Tablets: Initial: 500 to 750 mcg usually produces a detectable effect in 0.5 to 2 hours with a maximal effect in 2 to 6 hours. Additional doses of 125 to 375 mcg may be given at 6 to 8 hour intervals until clinical evidence of an adequate effect is noted. The usual amount of digoxin tablets that a 70 kg patient requires to achieve 8 to 12 mcg/kg peak body stores is 750 to 1250 mcg. Injection: Initial: 400 to 600 mcg of digoxin intravenously usually produces a detectable effect in 5 to 30 minutes with a maximal effect in 1 to 4 hours. Additional doses of 100 to 300 mcg may be given cautiously at 6 to 8 hour intervals until clinical evidence of an adequate effect is noted. The usual amount of digoxin injection that a 70 kg patient requires to achieve 8 to 12 mcg/kg peak body stores is 600 to 1000 mcg.
Route of Administration: Other
In Vitro Use Guide
Digoxin was effective against B. mandrillaris at 250uM
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:07:22 GMT 2023
Edited
by admin
on Fri Dec 15 15:07:22 GMT 2023
Record UNII
73K4184T59
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Digoxin
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
DYNAMOS
Common Name English
DIGOXIN [IARC]
Common Name English
STILLACOR-
Common Name English
LANOCARDIN
Common Name English
DIGOXIN [WHO-IP]
Common Name English
DIGOXIN [MI]
Common Name English
Digoxin [WHO-DD]
Common Name English
TOLOXIN
Common Name English
MAPLUXIN
Common Name English
DIGOXIN [VANDF]
Common Name English
DIGOXIN [EP MONOGRAPH]
Common Name English
DIGOXIN [HSDB]
Common Name English
3.BETA.-((O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-12.BETA.,14-DIHYDROXY-5.BETA.-CARD-20(22)-ENOLIDE
Common Name English
DIGOXINUM [WHO-IP LATIN]
Common Name English
NATIGOXIN
Common Name English
digoxin [INN]
Common Name English
DIGOXIN [USP-RS]
Common Name English
DIGOXIN [MART.]
Common Name English
DIGOXIN [JAN]
Common Name English
DIGOXIN [USP MONOGRAPH]
Common Name English
VANOXIN
Common Name English
CARD-20(22)-ENOLIDE, 3-((O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-12,14-DIHYDROXY-,(3.BETA.,5.BETA.,12.BETA.)-
Common Name English
NSC-95100
Code English
DIGOXIN [ORANGE BOOK]
Common Name English
LANOXIN
Brand Name English
ROUGOXIN
Common Name English
FARGOXIN
Common Name English
Classification Tree Code System Code
NDF-RT N0000175568
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
WHO-VATC QC01AA05
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 12.2
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
NCI_THESAURUS C823
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
LIVERTOX 307
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
NDF-RT N0000008157
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
NDF-RT N0000008157
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
CFR 21 CFR 862.3320
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 12.4
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
NCI_THESAURUS C78322
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
WHO-ATC C01AA05
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
Code System Code Type Description
ECHA (EC/EINECS)
244-068-1
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
HSDB
214
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
MERCK INDEX
m4456
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID5022934
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
CAS
20830-75-5
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
SMS_ID
100000091378
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
EVMPD
SUB07135MIG
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
RXCUI
3407
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY RxNorm
CHEBI
145795
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
ChEMBL
CHEMBL1751
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
INN
389
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
WIKIPEDIA
DIGOXIN
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
NSC
95100
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
LACTMED
Digoxin
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
DRUG CENTRAL
882
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
DRUG BANK
DB00390
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
NCI_THESAURUS
C28990
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
IUPHAR
4726
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
CHEBI
4551
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
FDA UNII
73K4184T59
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
MESH
D004077
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
RS_ITEM_NUM
1200000
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
DAILYMED
73K4184T59
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
PUBCHEM
2724385
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DIGOXIN
Created by admin on Fri Dec 15 15:07:22 GMT 2023 , Edited by admin on Fri Dec 15 15:07:22 GMT 2023
PRIMARY Description: Colourless crystals or a white or almost white, crystalline powder; odourless.Solubility: Practically insoluble in water and ether R; freely soluble in pyridine R; slightly soluble in ethanol (~750 g/l) TS.Category: Cardiotonic.Storage: Digoxin should be kept in a well-closed container, protected from light.Additional information: CAUTION: Digoxin is extremely poisonous and should be handled with care.Requirements : Definition. Digoxin contains not less than 95.0% and not more than 103.0% of C41H64O14, calculated with reference to the driedsubstance.
Related Record Type Details
OATP-8
TRANSPORTER -> SUBSTRATE
MDR-3
TRANSPORTER -> SUBSTRATE
OATP-8
TRANSPORTER -> INHIBITOR
OATP1B1
TRANSPORTER -> INHIBITOR
OVINE DIGOXIN IMMUNE FAB
INHIBITOR -> TARGET
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
in vitro ER in the MDCK-MDR1 cell line from National Institutes of Health
EFFLUX RATIO
Related Record Type Details
Structure of METILDIGOXIN
PARENT -> METABOLITE
Metabolite to parent drug ratio in non-uraemic human plasma. The N-desmethyl metabolite has similar efficacy as the parent drug in the treatment of patients with petit mal epilepsy.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
Structure of DIGOXIGENIN 3-O-SULFATE
METABOLITE -> PARENT
Structure of DIHYDRODIGOXIN
METABOLITE -> PARENT
MAJOR
PLASMA
Structure of 3-OXODIGOXIGENIN
METABOLITE -> PARENT
Structure of DIGOXIGENIN
METABOLITE -> PARENT
Structure of DIGOXIGENIN-3-GLUCURONIDE
METABOLITE -> PARENT
Related Record Type Details
Structure of DIGOXOSIDE
IMPURITY -> PARENT
Structure of DIGOXIGENIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3.BETA.-(2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYLOXY)-12.BETA.,14-DIHYDROXY-5.BETA.-CARD-20(22)-ENOLIDE
IMPURITY -> PARENT
Structure of LANATOSIDE C
IMPURITY -> PARENT
Structure of .BETA.-ACETYLDIGOXIN
IMPURITY -> PARENT
Structure of BISDIGOXIGENIN
IMPURITY -> PARENT
Structure of GITOXIN
IMPURITY -> PARENT
Structure of DIGINATIN
IMPURITY -> PARENT
Structure of Digitoxin
IMPURITY -> PARENT
Related Record Type Details
Structure of Digoxin
ACTIVE MOIETY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966